Watch for FDA meeting outcomes and Phase 3 trial initiation details. The 73% ORR in a hard-to-treat population is promising but based on only 11 patients at the highest dose; larger cohort data (up to 100 patients) will be critical. No revenue impact until regulatory approval, which is years away.
Price Chart
Executive Summary
Regeneron announced first clinical data for ubamatamab (MUC16xCD3 bispecific) in low-grade serous ovarian cancer (LGSOC) at IGCS 2026, showing a 73% objective response rate and 11-month median progression-free survival at the 800 mg dose in heavily pre-treated patients. The company is enrolling a potentially registrational cohort and plans a confirmatory Phase 3 trial, with FDA discussions expected in coming months. This is an early-stage, non-regulatory data readout for an investigational asset with no approved status, making it a notable but not transformative catalyst for a large-cap biotech.
Key Facts
- 73% objective response rate (ORR) at 800 mg ubamatamab monotherapy in 11 patients with recurrent, heavily pre-treated LGSOC
- 11-month median progression-free survival (PFS) at 800 mg dose
- 9-month median duration of response at 800 mg dose
- Cytokine release syndrome occurred in 90% of patients (all Grade 1-2); no treatment-related deaths
- Regeneron is enrolling a single-arm, potentially registrational LGSOC cohort and plans a confirmatory Phase 3 trial
- Company will discuss data with FDA in coming months
- LGSOC comprises up to 10% of serous ovarian cancer; historical ORR below 15% with chemo/endocrine therapy
Financial Impact
No financial figures provided; ubamatamab is investigational with no approved status or revenue. LGSOC is a niche indication (up to 10% of ovarian cancer, ~21,010 new U.S. cases annually).
Risk Factors
- Data based on small sample (11 patients at 800 mg); response rates may not replicate in larger Phase 3 trial
- Ubamatamab is investigational; safety and efficacy not yet evaluated by any regulatory authority
- LGSOC is a relatively small market; commercial upside limited compared to broader oncology indications
- Cytokine release syndrome (90% incidence) requires careful management; could limit tolerability in broader population
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 25, 2026 2d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 23, 2026 4d ago | Institutional Cluster | $805.02 | awaiting T+5 | — | $816.10 (−1.38%) |
Oct 15, 2026 12d ago | ANALYST-UPGRADE | $790.74 $805.02 | ▲ +1.81% | ▲ +2.24% | $816.10 (+3.21%) |
Oct 14, 2026 13d ago | 144 | $796.34 $819.09 | ▲ +2.86% | ▲ +3.87% | $816.10 (+2.48%) |
Oct 6, 2026 21d ago | 8-K | $738.72 $753.12 | ▲ +1.95% | ▲ +2.09% | $816.10 (+10.47%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Oct 1, 2026 27d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers